Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty
โ Scribed by Gurbel, Paul A. ;Navetta, Frank I. ;Bates, Eric R. ;Muller, David W. ;Tenaglia, Alan N. ;Miller, Michael J. ;Muhlstein, Brent ;Hermiller, James B. ;Davidson, Charles J. ;Aguirre, Frank V. ;Beauman, Glenn J. ;Berdan, Lisa G. ;Leimberger, Jeffrey D. ;Bovill, Edwin G. ;Christenson, Robert H. ;Ohman, E. Magnus
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 932 KB
- Volume
- 37
- Category
- Article
- ISSN
- 0098-6569
No coin nor oath required. For personal study only.
โฆ Synopsis
Percutaneous coronary revascularization in patients with unstable angina and coronary thrombus carries a high complication rate. A new strategy to reduce thrombus burden before revascularization was tested in a multicenter prospective trial. Patients with unstable angina and coronary thrombus (n = 45) received alteplase through an infusion catheter at the proximal aspect of the target lesion and concomitant intracoronary heparin via a standard guiding catheter. Angiography was performed before and after lesiondirected therapy and post-intervention. Systemic fibrinogen depletion and thrombin activation were not observed, while fibrinolysis was evident for 2 4 hr after treatment. Target lesion stenosis did not change significantly after lesion-directed therapy, but thrombus score was reduced, particularly among patients who had large thrombi (mean 2.2 vs. 1.6, P = 0.02). Revascularization was successful in 89% of patients. Median final stenosis was 30% and mean final thrombus score was 0.4. Complications included recurrent ischemia (llY0), MI (7%), abrupt closure (7%), severe bleeding (4%), and repeat emergency angioplasty (2%). Patients with overt thrombus appeared to derive the most angiographic benefit from lesion-directed alteplase plus intracoronary heparin. Later revascularization was highly successful. This strategy may be a useful adjunct to percutaneous revascularization for patients with unstable angina and frank intracoronary thrombus.
๐ SIMILAR VOLUMES
The use of abciximab during percutaneous coronary angioplasty (PTCA) in patients with unstable angina (UA) prevents the postintervention enzyme surge and improves clinical outcomes, possibly by improving microcirculatory function. The aim of this quantitative myocardial blush grade (MBG) study was t